Metraipolis › archive › dc_c9823ece161a

CCL3+ Neutrophil Signature Predicts Response to Neoadjuvant Toripalimab plus Chemotherapy in Patients with Hypopharyngeal Squamous Cell Carcinoma: A Phase II… — Europe PMC PMID:41817286

Source
Europe PMC (en)
Original
https://europepmc.org/article/MED/41817286
DOI
10.1158/1078-0432.ccr-25-4096
License (as archived)
solo-consultazione
Archived
2026-10-31T23:30:44.087Z
SHA-256 of the archived text
1b863deb7c42658755567cbd9b3421a213b305f8b686db8673109e27fbde6785
Stable URL of this page
https://metraipolis.com/documento/dc_c9823ece161a

How to cite

CCL3+ Neutrophil Signature Predicts Response to Neoadjuvant Toripalimab plus Chemotherapy in Patients with Hypopharyngeal Squamous Cell Carcinoma: A Phase II… — Europe PMC PMID:41817286 — Europe PMC (en), https://europepmc.org/article/MED/41817286 (solo-consultazione); archived copy: https://metraipolis.com/documento/dc_c9823ece161a (Metraipolis archive dc_c9823ece161a, sha256 1b863deb7c42658755567cbd9b3421a213b305f8b686db8673109e27fbde6785)
BibTeX
@misc{dcc9823ece161a,
  title = {CCL3+ Neutrophil Signature Predicts Response to Neoadjuvant Toripalimab plus Chemotherapy in Patients with Hypopharyngeal Squamous Cell Carcinoma: A Phase II… — Europe PMC PMID:41817286},
  howpublished = {Europe PMC (en)},
  url = {https://europepmc.org/article/MED/41817286},
  note = {License solo-consultazione; archived copy https://metraipolis.com/documento/dc_c9823ece161a; sha256 1b863deb7c42658755567cbd9b3421a213b305f8b686db8673109e27fbde6785},
  year = {2026}
}

Archived text

The text is not reproduced here: the archive holds it as solo-consultazione (consultation only, no republication). Read it at the original source: https://europepmc.org/article/MED/41817286. Agents can read the archived copy with the MCP tool read_document.